Novartis Galvus "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis will likely have to conduct another clinical trial of its dipeptidyl peptidase-4 inhibitor Galvus (vildagliptin) following a Feb. 23 "approvable" letter. FDA had earlier requested a three-month extension of the initial November 2006 user fee date due to concerns about necrotoxicity seen in preclinical studies. Novartis said FDA remains concerned about the skin toxicity and that some patients may be predisposed to achieving high plasma levels with standard doses. FDA requested that all manufacturers developing DPP-4 agents characterize their compounds' dermatologic safety profiles. Cleared in October, FDA did not see skin toxicity in Merck's Januvia (sitagliptin), which was the first DPP-4 inhibitor to be approved (1Pharmaceutical Approvals Monthly January 2007, p. 29)...
You may also be interested in...
Novartis extends Galvus resubmission target to mid-‘09
An FDA-requested safety study of Novartis' antidiabetic Galvus (vildagliptin) will take at least six months, not "weeks" as the firm originally suggested, and will enroll "several hundred" patients with renal impairment, Head of Pharma Development James Shannon tells a July 17 earnings call. The study, requested in FDA's Feb. 23 "approvable" letter for the dipeptidyl peptidase-4 agent, responds to concerns about skin lesions seen in primates and healthy volunteers at four to six times the proposed therapeutic dose, Shannon said. FDA is concerned that susceptible populations may get to those levels, he explained. FDA has requested that all manufacturers developing DPP-4 agents characterize their compounds' dermatologic safety profiles (1Pharmaceutical Approvals Monthly March 2007, p. 20). Novartis submitted a study protocol in June and, if FDA agrees, anticipates starting the renal impairment study in the fourth quarter of 2007. "We would resubmit the dossier to the FDA sometime in mid-2009," Shannon predicted…
DeCODE Heart Attack Drug To Return To Phase III With Expanded Study Population
DeCODE Genetics has expanded the patient population for its Phase III trial of its lead compound DG031 to include all patients who carry a variant of one of the genes the company has linked to risk of heart attack via the leukotriene pathway.
Skin Toxicity Seen In Other DPP-4 Inhibitors Missing In Januvia – FDA Review
FDA requested that Merck conduct an additional study in primates during its review of Januvia (sitagliptin) due to concerns of necrotoxicity based on similar findings seen with other DPP-4 inhibitors.